456 Pilot study of topical itraconazole for the treatment of basal cell carcinomas in gorlin syndrome patients

This study aimed to (1) determine whether 4-12 weeks of itraconazole 0.7% gel reduces GLI1 mRNA levels, the target of the hedgehog signaling pathway and a biomarker for basal cell carcinoma (BCC) and (2) assess whether itraconazole gel reduces BCC tumor area in Gorlin syndrome patients. This open label, intra-patient study enrolled 9 Gorlin syndrome patients with a total of 107 tumors. Seven patients were male; the majority (67%) was non-Hispanic white with mean age of 54 years. Each patient contributed at least 4 target BCCs: one tumor was collected at baseline for GLI1 mRNA, one or more were treated with placebo gel twice daily (BID), and 2 or more were treated with itraconazole 0.7% gel BID for 4 to 12 weeks.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Pathophysiology and Therapeutics Source Type: research